A detailed history of Sg Americas Securities, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Sg Americas Securities, LLC holds 35,331 shares of VRTX stock, worth $17.8 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
35,331
Previous 78,529 55.01%
Holding current value
$17.8 Million
Previous $36.8 Million 55.36%
% of portfolio
0.06%
Previous 0.21%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 03, 2024

SELL
$460.0 - $505.78 $19.9 Million - $21.8 Million
-43,198 Reduced 55.01%
35,331 $16.4 Million
Q2 2024

Jul 12, 2024

BUY
$392.81 - $485.53 $19 Million - $23.5 Million
48,495 Added 161.47%
78,529 $36.8 Million
Q1 2024

May 06, 2024

BUY
$407.69 - $446.08 $779,095 - $852,458
1,911 Added 6.8%
30,034 $12.6 Million
Q4 2023

Jan 12, 2024

BUY
$343.0 - $410.68 $4.95 Million - $5.92 Million
14,427 Added 105.34%
28,123 $11.4 Million
Q3 2023

Oct 13, 2023

SELL
$338.18 - $362.46 $5.53 Million - $5.93 Million
-16,367 Reduced 54.44%
13,696 $4.76 Million
Q2 2023

Jul 10, 2023

BUY
$314.42 - $351.91 $4.24 Million - $4.75 Million
13,487 Added 81.36%
30,063 $10.6 Million
Q1 2023

Apr 28, 2023

SELL
$283.23 - $323.1 $529,356 - $603,873
-1,869 Reduced 10.13%
16,576 $5.22 Million
Q4 2022

Feb 02, 2023

BUY
$285.76 - $321.48 $1.18 Million - $1.32 Million
4,112 Added 28.69%
18,445 $5.33 Million
Q3 2022

Oct 31, 2022

SELL
$273.83 - $305.53 $6.92 Million - $7.73 Million
-25,284 Reduced 63.82%
14,333 $4.15 Million
Q2 2022

Jul 29, 2022

SELL
$234.96 - $292.55 $8.38 Million - $10.4 Million
-35,668 Reduced 47.38%
39,617 $11.2 Million
Q1 2022

Apr 29, 2022

BUY
$221.42 - $260.97 $9.11 Million - $10.7 Million
41,131 Added 120.43%
75,285 $19.6 Million
Q4 2021

Feb 07, 2022

BUY
$177.01 - $223.45 $4.58 Million - $5.79 Million
25,894 Added 313.49%
34,154 $7.5 Million
Q3 2021

Nov 01, 2021

SELL
$181.39 - $202.99 $20.9 Million - $23.3 Million
-114,990 Reduced 93.3%
8,260 $1.5 Million
Q2 2021

Aug 12, 2021

BUY
$187.49 - $221.1 $17.2 Million - $20.3 Million
91,977 Added 294.11%
123,250 $24.9 Million
Q1 2021

May 13, 2021

SELL
$207.02 - $241.31 $2.9 Million - $3.38 Million
-13,996 Reduced 30.92%
31,273 $6.72 Million
Q4 2020

Feb 04, 2021

BUY
$207.01 - $276.09 $3.35 Million - $4.47 Million
16,177 Added 55.61%
45,269 $10.7 Million
Q3 2020

Nov 09, 2020

SELL
$255.65 - $303.1 $4 Million - $4.74 Million
-15,628 Reduced 34.95%
29,092 $7.92 Million
Q2 2020

Jul 20, 2020

BUY
$225.48 - $295.8 $5.18 Million - $6.79 Million
22,953 Added 105.45%
44,720 $13 Million
Q1 2020

Apr 30, 2020

BUY
$199.77 - $247.81 $174,798 - $216,833
875 Added 4.19%
21,767 $5.18 Million
Q4 2019

Jan 28, 2020

SELL
$166.71 - $223.91 $11.4 Million - $15.3 Million
-68,170 Reduced 76.54%
20,892 $4.57 Million
Q3 2019

Nov 04, 2019

BUY
$166.23 - $187.09 $9.15 Million - $10.3 Million
55,071 Added 162.02%
89,062 $15.1 Million
Q2 2019

Jul 29, 2019

BUY
$164.61 - $190.37 $2.92 Million - $3.37 Million
17,724 Added 108.96%
33,991 $6.23 Million
Q1 2019

Apr 29, 2019

BUY
$163.73 - $194.7 $2.35 Million - $2.79 Million
14,328 Added 738.94%
16,267 $2.99 Million
Q4 2018

Feb 01, 2019

SELL
$151.91 - $192.21 $12.9 Million - $16.3 Million
-84,768 Reduced 97.76%
1,939 $321,000
Q3 2018

Nov 06, 2018

BUY
$167.73 - $192.74 $8.19 Million - $9.42 Million
48,849 Added 129.03%
86,707 $16.7 Million
Q2 2018

Aug 07, 2018

SELL
$145.72 - $169.96 $4.21 Million - $4.91 Million
-28,889 Reduced 43.28%
37,858 $6.43 Million
Q1 2018

May 03, 2018

BUY
$151.6 - $177.13 $7.81 Million - $9.13 Million
51,539 Added 338.89%
66,747 $10.9 Million
Q4 2017

Jan 24, 2018

SELL
$137.28 - $155.55 $10,158 - $11,510
-74 Reduced 0.48%
15,208 $2.28 Million
Q3 2017

Nov 07, 2017

BUY
$148.13 - $162.24 $2.26 Million - $2.48 Million
15,282
15,282 $2.32 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Sg Americas Securities, LLC Portfolio

Follow Sg Americas Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sg Americas Securities, LLC with notifications on news.